Genetic Epidemiology of Glioma-International Consortium
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 09-007013
Sponsor Protocol Number: 09-007013
About this study
The purpose of this study is to identify common genetic variants contributing to the risk of glioma. Evaluate gene-gene and gene-environmental interactions with strong biologic relevance to identify gene-gene and gene-environment interactions for glioma risk.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Histologically proven glioma will include:
- GBM Cases must be identified at the site within 12 months of 1st glioma pathology date (biopsy or resection).
- Consent, blood, and questionnaire must be completed within 18 months of 1st pathology date (biopsy or resection).
- Non-GBM cases must be identified at the site within 36 months of 1st glioma pathology date (biopsy or resection).
- Consent, blood and questionnaire must be completed within 3.5 years of 1st pathology date.
- 1st imaging date will also be collected so glioma patients who were diagnosed via imaging years before a surgery diagnosis (watchful-waiting) can be excluded if necessary at a later date.
- Secondary glioma cases (recurrence and progression of disease are excluded).
- Eligible Glioma Subtypes:
- Glioma Histology (first pathology/surgery):
- Astroblastoma
- Astrocytoma, anaplastic
- Astrocytoma, diffuse
- Astrocytoma, fibrillary
- Astrocytoma, gemistocytic
- Astrocytoma, protoplasmic
- Astrocytoma, unclassified
- Ependymoma
- Ependymoblastoma
- Ependymoma, anaplastic
- Ependymoma, myxopapillary
- Ependymoma, tancytic
- Giant cell glioblastoma multiforme
- Glioblastoma mutliforme
- Glioma, unclassified anaplastic
- Glioma, unclassified
- Gliomatosis cerebri
- Gliosarcoma
- Oligoastrocytoma
- Oligodendroglioma
- Oligodendroglioma, anaplastic
- Oligostrocytoma, anaplastic
- Pleomorphic xanthoastrocytoma
- Subependyomoma
- Glioma Topography (first pathology/surgery):
- Brain Stem
- Cerebellum
- Cerebrum
- Cranial Nerve, NOS
- Cytology, ventricular fluid
- Intracranial site, NOS
- Suprasellar region
- Age 18 to 80
- Willing to complete questionnaire and donate 30 ml of blood and/or provide a saliva sample
- The blood sample and questionnaire will be obtained from IRB# 12-003458.
- English speaking participants only.
Control Accrual- (These Subjects will be obtained from IRB#08-007049)
- Age 18 to 80
- Willing to complete questionnaire and donate 30 ml of blood and/or provide saliva sample
- English speaking participants only.
- Never diagnosed with cancer.
Exclusion Criteria:
- Pregnant women
- Pediatrics
- Prisoners will be excluded
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
More information
Publications
Publications are currently not available